CoChat

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Open access

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Pharmacological PP2A activation is a druggable approach to overcome MEK inhibitor resistance.

Overview

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aaq1093

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

1 retracted

Show all 49 references

Cited by

See all 149

Metadata

Authors
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., Haapaniemi, P., Momeny, M., Varila, T., Ohlmeyer, M., Aittokallio, T., Wennerberg, K., Narla, G., & Westermarck, J.
Affiliations
  • Åbo Akademi University (FI)
  • Case Comprehensive Cancer Center (US)
  • University of Helsinki (FI)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
  • O’Connor, Caitlin M.
  • Kulesskiy, Evgeny
  • Narla, Goutham
  • Westermarck, Jukka
Venue
Science Translational Medicine
Published
2018-07-18
Volume
10
Issue
450
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2884137656
Cited by
149
References
48
Citations by year
2026: 12 · 2025: 12 · 2024: 14 · 2023: 21 · 2022: 22 · 2021: 24 · 2020: 19 · 2019: 20 · 2018: 5
FWCI
6.04
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • NIH Office of the Director (R01 CA181654)
  • Sigrid Juséliuksen Säätiö
  • Academy of Finland (252572, 294850, 310507, 277293)
  • Cancer Society of Finland
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
protein phosphatase 2A, PP2A inhibition, MEK inhibitor resistance, KRAS-mutant lung cancer, Akt/mTOR signaling, selumetinib, kinase inhibitor resistance, serine/threonine phosphatase, combination therapy
MeSH terms
Animals, Humans, Lung Neoplasms, Male, Mice, Inbred BALB C, Mice, Nude, Mutation, Signal Transduction, Proto-Oncogene Proteins p21(ras), Cellular Senescence, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Protein Phosphatase 2, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. https://app.cochat.ai/papers/10.1126/scitranslmed.aaq1093
The paper
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., Haapaniemi, P., Momeny, M., Varila, T., Ohlmeyer, M., Aittokallio, T., Wennerberg, K., Narla, G., & Westermarck, J. (2018). PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aaq1093

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.